UMMS Affiliation

Department of Medicine, Division of Endocrinology and Metabolism

Publication Date

2019-05-14

Document Type

Letter to the Editor

Disciplines

Cardiovascular Diseases | Endocrine System Diseases | Endocrinology, Diabetes, and Metabolism | Nutritional and Metabolic Diseases

Abstract

SGLT2 inhibitor (SGLT2i) class of medications are known to cause to euglycemic diabetic ketoacidosis (euDKA) as reported in the article by Lin et al. in your esteemed publication about this entity being reported for the first time in Taiwanese population.We wish to share the findings from our center to further expand the spectrum of findings associated with SGLT2i therapy.

Keywords

Cardiovascular, Euglycemic-diabetic ketoacidosis, Ketonemia, SGLT2

Rights and Permissions

Copyright 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

DOI of Published Version

10.1016/j.jfma.2019.04.021

Source

J Formos Med Assoc. 2019 May 14. pii: S0929-6646(19)30390-0. doi: 10.1016/j.jfma.2019.04.021. [Epub ahead of print] Link to article on publisher's site

Journal/Book/Conference Title

Journal of the Formosan Medical Association = Taiwan yi zhi

Related Resources

Link to Article in PubMed

PubMed ID

31101495

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.